NCT00313196View on ClinicalTrials.gov

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Pulmonary Hypertension
Interventions
DRUG

bosentan

Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY